Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mixed Chimerism for Hemoglobinopathies
NCT01419704Phase 2Withdrawn
- Sponsor
- Talaris Therapeutics
- Start
- May 2011
- Primary completion
- May 2016
- Countries
- 1
01
Overview
A Phase 2 trial of FCR001 in sickle cell disease (SCD), thalassemia, Diamond-Blackfan anemia (DBA), bone marrow failure syndrome (BMFS), sponsored by Talaris Therapeutics. Planned start May 2011; status: withdrawn.
02
Drugs
FCR001
03
Conditions
sickle cell disease (SCD)thalassemiaDiamond-Blackfan anemia (DBA)bone marrow failure syndrome (BMFS)
Beyond the preview
Go deeper on NCT01419704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01419704.